Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-047798
Filing Date
2025-03-31
Accepted
2025-03-31 16:30:34
Documents
100
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K grtx-20241231.htm   iXBRL 10-K 3321035
2 EX-4.2 grtx-ex4_2.htm EX-4.2 51929
3 EX-10.20 grtx-ex10_20.htm EX-10.20 257981
4 EX-10.21 grtx-ex10_21.htm EX-10.21 98785
5 EX-19.1 grtx-ex19_1.htm EX-19.1 147607
6 EX-21.1 grtx-ex21_1.htm EX-21.1 6007
7 EX-23.1 grtx-ex23_1.htm EX-23.1 2772
8 EX-31.1 grtx-ex31_1.htm EX-31.1 13376
9 EX-31.2 grtx-ex31_2.htm EX-31.2 13332
10 EX-32.1 grtx-ex32_1.htm EX-32.1 8690
11 EX-32.2 grtx-ex32_2.htm EX-32.2 8649
  Complete submission text file 0000950170-25-047798.txt   12947584

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT grtx-20241231.xsd EX-101.SCH 1908818
103 EXTRACTED XBRL INSTANCE DOCUMENT grtx-20241231_htm.xml XML 1836377
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39114 | Film No.: 25793779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)